Authors
Latest:
Squamous Cell Carcinoma of the Kidney: A Large Case SeriesSyed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.
Latest:
Molecular Profiling in Metastatic Colorectal CancerABSTRACT: Colorectal cancer (CRC) is a commonly diagnosed malignancy. Although chemotherapy remains the backbone of treatment, the landscape of treating metastatic CRC (mCRC) is changing with the understanding of its heterogeneity and molecular blueprint. Colon cancer sidedness has proven to hold prognostic implications, with right-sided tumors having higher incidence of BRAF and KRAS mutations and being microsatellite instability–high (MSI-H); overall, they have a worse prognosis compared with left sided-tumors. Results of molecular research have demonstrated the need to profile each mCRC patient for RAS and BRAF mutations, MSI-H status, HER2 amplifications, and NTRK fusions. Ongoing clinical trials using targeted agents aim to further improve survival outcomes. We emphasize the epidemiology, knowledge of primary tumor location, and mutational landscape of mCRC, as well as novel treatment options for patients harboring unique subtypes of these characteristics.
Latest:
Collaborative Care and Access Challenges in Managing R/R MM with GPRC5D BispecificOncology Clinical Pharmacist Specialist Amir Ali delves into potential challenges related to access and the use of this therapy, providing a comprehensive perspective on the complexities of incorporating GPRC5-targeting bispecifics into R/R MM patient management.
Latest:
Perioperative Telemonitoring Yields “Encouraging” Results in GI CancersPatient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Latest:
Oncology Peer Review On-The-Go Podcast: Cervical Cancer Screenings/Survival in Those 65+ YearsJulianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLCMisako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, emphasize the importance of patient education, discussing how understanding the biological reasons behind treatments for EGFR-mutated non-small cell lung cancer and their side effects can lead to better outcomes, and highlighting the need for collaborative care and clear communication.
Latest:
Treatment Considerations for Bispecific Antibodies and Unmet Needs in MMThe expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.
Latest:
FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic LeukemiaThe updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.
Latest:
Exploring New Possibilities in Kidney Cancer Detection and TherapyExperts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.
Latest:
Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Key Highlights of the Phase 3 ASPEN TrialThe trial evaluated zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.
Latest:
Identifying Indications for Neoadjuvant Therapy in CholangiocarcinomaThe recent Hot Topics section focuses on survival rates for patients with cholangiocarcinoma.
Latest:
Recent Advances in the Understanding of MCL BiologyElias Campo, MD, PhD, provides insight into biological subtyping and the tumor microenvironment relating to mantle cell lymphoma.
Latest:
Isatuximab Combo Yields MRD-Negative Responses in Transplant-Eligible NDMMNearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.
Latest:
Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate CancerONCOLOGY® editorial board member E. David Crawford, MD, and colleagues, propose a new model for guiding the treatment of prostate cancer that focuses on a “transitional state,” which occurs during the interval of progression to metastatic castration-resistant prostate cancer.
Latest:
Striving for Health Care Equity by Closing the Cancer Care Gap“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”
Latest:
Cross Q&A: Role of Belantamab Mafodotin in MMThe panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Oncology Peer Review On-The-Go: BPCIA, 4-Letter Suffix Rule, & the Challenges of Prescribing BiosimilarsCancerNetwork®’s podcast hosted 2 experts to discuss the current state of biosimilar prescriptions and the need for change to improve the system overall.
Latest:
Exploring New Possibilities in Kidney Cancer Detection and TherapyExperts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.
